Recent News

• 03.04.2026 - Harmony Biosciences to Participate in Upcoming Investor Conferences
• 02.24.2026 - Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
• 02.17.2026 - Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
• 02.10.2026 - Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
• 01.12.2026 - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Recent Filings

• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.24.2026 - 8-K Current report
• 02.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities